Analyst Edward White from H.C. Wainwright reiterated a Buy rating on InflaRx (IFRX – Research Report) and keeping the price target at $8.00.
Edward White’s rating is based on several promising developments regarding InflaRx’s lead product, Gohibic (vilobelimab). The company has presented multiple posters at the 2025 American Academy of Dermatology Annual Meeting, highlighting Gohibic’s potential in treating pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS). These presentations included positive safety and efficacy data from Phase 2 trials, showing that Gohibic is well-tolerated and effective in reducing disease symptoms.
Moreover, Gohibic has received significant regulatory support, including Emergency Use Authorization for COVID-19 treatment and Fast Track Designation for PG from the FDA. The ongoing Phase 3 study for PG, with interim results expected in the second quarter of 2025, further strengthens the outlook. Additionally, the company’s financial projections, including a forecasted 2027 launch for Gohibic in PG and a probability-adjusted revenue model, support the Buy rating with a price target of $8.00.
According to TipRanks, White is an analyst with an average return of -3.2% and a 35.38% success rate. White covers the Healthcare sector, focusing on stocks such as Valneva, 60 Degrees Pharmaceuticals, Inc., and Chimerix.